Abstract
Numerous basic-helix-loop-helix (bHLH) transcription factors (TF) have been found to play important roles in tumor growth and progression. Elucidation of the common features of these TFs can pave the road to possible therapeutic intervention. The existing studies of possible inhibition of these TFs are concentrated on the development of peptides or small molecules that inhibit their dimerization or prevent their DNA binding. The bHLH TFs have striking similarity in many functionally important regions, such as the helical regions of TFs that interact with each other during dimerization and have complementary sets of residues on both sides of a dimer. These are hydrophobic residues along with anionic and cationic residues with complementary charges. Such complementarity also exists in other contact regions of the bHLH TFs. They also have a very specific set of positively charged residues on the surface, which would contact DNA. Such specificity defines a common concept for an in silico design of bHLH TFs inhibitors for a number of existing and important cancer-related TFs.
Keywords: bHLH, cancer, computational drug design, drug-DNA interactions, drug–protein interactions, inhibitors, in silico, protein dimerization, transcription factor.
Current Medicinal Chemistry
Title:bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design
Volume: 21 Issue: 28
Author(s): I.F. Tsigelny, V.L. Kouznetsova, S.C. Pingle and S. Kesari
Affiliation:
Keywords: bHLH, cancer, computational drug design, drug-DNA interactions, drug–protein interactions, inhibitors, in silico, protein dimerization, transcription factor.
Abstract: Numerous basic-helix-loop-helix (bHLH) transcription factors (TF) have been found to play important roles in tumor growth and progression. Elucidation of the common features of these TFs can pave the road to possible therapeutic intervention. The existing studies of possible inhibition of these TFs are concentrated on the development of peptides or small molecules that inhibit their dimerization or prevent their DNA binding. The bHLH TFs have striking similarity in many functionally important regions, such as the helical regions of TFs that interact with each other during dimerization and have complementary sets of residues on both sides of a dimer. These are hydrophobic residues along with anionic and cationic residues with complementary charges. Such complementarity also exists in other contact regions of the bHLH TFs. They also have a very specific set of positively charged residues on the surface, which would contact DNA. Such specificity defines a common concept for an in silico design of bHLH TFs inhibitors for a number of existing and important cancer-related TFs.
Export Options
About this article
Cite this article as:
Tsigelny I.F., Kouznetsova V.L., Pingle S.C. and Kesari S., bHLH Transcription Factors Inhibitors for Cancer Therapy: General Features for In Silico Drug Design, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140414111333
DOI https://dx.doi.org/10.2174/0929867321666140414111333 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Cucurbitacin B Enhances the Anticancer Effect of Imatinib Mesylate Through Inhibition of MMP-2 Expression in MCF-7 and SW480 Tumor Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Anticancer Drug Design Using Scaffolds of β-Lactams, Sulfonamides, Quinoline, Quinoxaline and Natural Products. Drugs Advances in Clinical Trials
Current Medicinal Chemistry Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Influence of the Bystander Effect on HSV-tk / GCV Gene Therapy. A Review.
Current Gene Therapy DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Synthesis and In vitro/In vivo Characterization of Raloxifene Grafted Poly(Styrene Maleic Acid)-Poly(Amide-Ether-Ester-Imide) Micelles for Targeted Delivery of Docetaxel in G Protein-Coupled Estrogen Receptor Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Arsenic Trioxide Exerts Anti-lung Cancer Activity by Inhibiting Angiogenesis
Current Cancer Drug Targets The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets The Synergistic Effect of Humanized Monoclonal Antibodies Targeting Insulin-Like Growth Factor 1 Receptor (IGF-1R) and Chemotherapy
Current Drug Targets Targeting the Ubiquitin-Proteasome Pathway: An Emerging Concept in Cancer Therapy
Current Topics in Medicinal Chemistry Dual-Targeted Molecular Probes for Cancer Imaging
Current Pharmaceutical Biotechnology Nanomaterials of Natural Bioactive Compounds for Wound Healing: Novel Drug Delivery Approach
Current Drug Delivery The Metabolism and Toxicity of Quinones, Quinonimines, Quinone Methides, and Quinone-Thioethers
Current Drug Metabolism Somatostatin and its Analogs
Current Drug Targets CDC25A: A Rebel Within the CDC25 Phosphatases Family?
Anti-Cancer Agents in Medicinal Chemistry Cytochrome P450-based Gene Therapy for Cancer Treatment: From Concept to the Clinic
Current Drug Metabolism GnRH Agonists and Antagonists in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents